Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CTNMBearishIndustry Newsnews

High materiality7/10

CTNM Tumbles on Mixed Admilarant Data; PIPE-791 Prospects in Focus

Oct 12, 2026, 1:18 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Mixed competitor data and a material 29% price drop signal near-term downside risk; sentiment hinges on PIPE-791 phase 2 signals and potential re-rating if results trend positive.

AI summary

What happened, with direct paths to the underlying reporting

Contineum Therapeutics slid after Bristol Myers Squibb reported mixed admilparant results for IPF, signaling LPAR1 competition risk. CTNM's PIPE-791 is in Phase 2 PROPEL-IPF with 324 patients, and topline endpoint is 26-week FVC change. Analysts view overall efficacy as meaningful, though the 120 mg dose raises dose-response questions, contributing to near-term volatility.

CTNM shares fell after BMY's admilparant Phase 3 results.
60 mg bid significantly slowed FVC decline; 120 mg not significant.
PIPE-791 PROPEL-IPF Phase 2 started with 324 IPF patients.
CTNM stock down 29.30% to $9.46 on news.
June publication details PIPE-791 discovery and brain-penetrant LPAR1 profile.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

CTNM Tumbles on Mixed Admilarant Data; PIPE-791 Prospects in Focus

CTNM Drops After Phase 2 MOONLIGHT-1 Misses Primary Endpoint

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value